Plateformes de biologie moléculaire en oncologie thoracique : quelles recherches, pour qui ?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Bulletin Du Cancer

• Publication date

  2013-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1684/BDC.2013.1774
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma

  2012cited by this paper
• Genetic insight and therapeutic targets in squamous-cell lung cancer

  2012cited by this paper
• EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR

  2012cited by this paper
• Étude de faisabilité de la recherche en routine des facteurs moléculaires de résistance aux inhibiteurs de tyrosine kinase de l’EGFR (EGFR-ITK) chez les patients atteints de cancer bronchique non à petites cellules (CBNPC) avec mutation de l’EGFR

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

  2011cited by this paper
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

  2011cited by this paper
• Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.

  2010cited by this paper
• F1000 highlights

  2009cited by this paper

• No citing papers are available for this paper.